Acorn Capital Advisors, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed May 19, 2025), Acorn Capital Advisors, LLC reported 21 stock positions worth $185.8 million. Its top holding was CG Oncology (CGON) at 17.5% of the portfolio, followed by Y-Mabs Therapeutics (YMAB, 12.1%) and Candel Therapeutics (CADL, 9.1%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0002054410
- Portfolio Value
- $185.8M (Q4 2024)
- SEC Filing
- 0001636587-25-000020 ↗ filed May 19, 2025
Holdings Value
Holdings 21 stocks · $185.8M
| CGON CG Oncology Inc. | 17.46% | 1,131,501 | $32.5M | — |
| YMAB Y-Mabs Therapeutics Inc. | 12.06% | 2,861,825 | $22.4M | — |
| CADL Candel Therapeutics Inc. | 9.06% | 1,939,644 | $16.8M | — |
| URGN Urogen Pharma Ltd. | 8.69% | 1,516,303 | $16.1M | — |
| PBYI Puma Biotechnology Inc. | 6.47% | 3,940,052 | $12.0M | — |
| BCAX Bicara Therapeutics Inc. | 6.03% | 643,381 | $11.2M | — |
| TERN Terns Pharmaceuticals Inc. | 5.88% | 1,971,264 | $10.9M | — |
| OKUR Onkure Therapeutics Inc. Class A | 5.51% | 1,439,674 | $10.2M | — |
| TRVI Trevi Therapeutics Inc. | 4.44% | 2,001,048 | $8.2M | — |
| TARA Protara Therapeutic Inc. | 3.64% | 1,279,800 | $6.8M | — |
| HELP Cybin Inc. | 3.49% | 734,393 | $6.5M | — |
| CRDF Cardiff Oncology Inc. | 3.37% | 1,442,308 | $6.3M | — |
| XFOR X4 Pharmaceuticals Inc. | 2.89% | 7,310,650 | $5.4M | — |
| MURA Mural Oncology PLC | 2.23% | 1,286,079 | $4.1M | — |
| WHWK Whitehawk Therapeutics Inc. filed as AADI BIOSCIENCE INC | 1.95% | 1,147,052 | $3.6M | — |
| OPTINOSE INC | 1.52% | 422,813 | $2.8M | — |
| QTTB Q32 Bio Inc. | 1.49% | 803,425 | $2.8M | — |
| ACRV Acrivon Therapeutics Inc. | 1.31% | 405,237 | $2.4M | — |
| BCAB Bioatla Inc. | 1.28% | 4,032,046 | $2.4M | — |
| VYNE THERAPEUTICS INC | 0.82% | 456,970 | $1.5M | — |
| VSTM Verastem Inc. | 0.42% | 779,498 | $779K | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 20 | $366.5M | CGON, URGN, TRVI, CADL, PBYI |
| Q1 2026 | 22 | $351.8M | TERN, CGON, URGN, PBYI, TRVI |
| Q4 2025 | 21 | $295.1M | TERN, CGON, URGN, TRVI, PBYI |
| Q3 2025 | 20 | $197.0M | CGON, URGN, PBYI, TRVI, TERN |
| Q2 2025 | 21 | $152.9M | CGON, URGN, YMAB, PBYI, CADL |
| Q1 2025Amended | 22 | $149.9M | CGON, URGN, YMAB, TRVI, CADL |
| Q4 2024Amended | 21 | $185.8M | CGON, YMAB, CADL, URGN, PBYI |